Who We Are

The Academy of Pharmaceutical Sciences (APS) is the UK-based professional membership body for Pharmaceutical Scientists.

We represent individuals and organisations from around the globe, throughout their development, in the delivery of excellence in the Pharmaceutical Science sector.

Pharmaceutical Scientists are experts in the research, development and manufacture of medicines. They have a major role in the regulation of medicines and understanding their use in patients.

What We Do

The APS is a not-for-profit organisation. We use revenues to champion innovation and opportunity in Pharmaceutical Sciences thereby improving the development and delivery of medicines for the benefit of patients. Our four key strategic themes, which are the foundation of all APS activities, are:

  • Establish and promote the reputation of Pharmaceutical Sciences and Scientists
  • Influence policy
  • Further scientific knowledge
  • Promote careers

APS Priorities

  • Ensure that we continue to deliver high quality scientific content to our members
  • Attract and retain a diverse and engaged membership community
  • Deliver a successful face to face PharmSci conference
  • Provide a vibrant Focus Group community with new groups aligned with current scientific areas
  • Promote and enhance diversity across our membership, board and fellows
  • Support and grow our accredited institution community

The APS Board & Advisory Board


Professor Hannah Batchelor

Position: APS Chair
Categories: The APS Board

Professor Hannah Batchelor is a Professor in pharmaceutics at the Strathclyde Institute of Pharmacy and Biomedical Science, University of Strathclyde in Glasgow.

Hannah is a pharmaceutical scientist who has worked in academia, the NHS and within the pharmaceutical industry. She works on the design and manipulation of medicines to create age appropriate drug formulations to maximise clinical efficacy in paediatric patients. Her research interests lie in the optimisation of drug formulations to maximise their biopharmaceutical performance and acceptability to children. Her research is informed by the views of children, young people and parents to ensure that the patients are at the centre of new developments.

Hannah is the current chair of the Academy of Pharmaceutical Sciences in the UK. She is still passionate about pharmaceutical sciences and is motivated to inspire the next generation of scientists.


Bob Clay

Position: APS Treasurer
Categories: The APS Board

Bob Clay established his regulatory consultancy practice through Highbury Regulatory Science in 2014 which supports small/medium size companies and their investors to develop regulatory/business strategies across multiple therapeutic and geographic areas. Before this, he was a VP of Global Regulatory Affairs at AstraZeneca with responsibility for oncology, infection, and personalised healthcare.

He is a member of the Expert Scientific Advisory Committee for Medicines for Malaria Venture (MMV) and works with several, not for profit organisations involved in global health initiatives. He was a board member of TOPRA (The Organisation of Professional Regulatory Affairs) from 2014 – 2018, and President for 2017.

Bob is a pharmacist with more than 30 years’ experience in drug development, leading the global regulatory approval of many products across a range of therapy areas including metabolic diseases, neuroscience, cancer, and infection, involving more than 15 new substances. Earlier in his career, he was a formulation scientist and pharmaceutical reviewer at UK regulatory agency. Bob has held significant leadership roles in regulatory affairs in regional and global functions at several companies including AstraZeneca and Pfizer and served as Chief Regulatory Officer at Kinapse (2014-2017).


Dr Kofi Asare-Addo

Position: Reader in Pharmaceutics, Admissions Tutor for Pharmacy (MPharm)
Categories: The APS Board

Dr Kofi Asare-Addo is a Reader in Pharmaceutics, Admissions Tutor for Pharmacy (MPharm) Course at the University of Huddersfield.

Kofi became a Fellow of the Higher Education Academy in 2014. His research area includes UV imaging in pharmaceuticals, particle engineering, drug-clay complexations for oral controlled release formulation applications and solubility enhancements (solid dispersions, salts and cocrystals). His work has been presented both nationally and internationally at various pharmaceutical science conferences. Kofi successfully collaborates with other universities and several pharmaceutical industries.


Arul Balasundaram

Position: Pharmaceutical Scientist
Categories: The APS Board
Arul Balasundaram:

Arul is a pharmaceutical scientist, who has extensive experience in product development of solids, liquids, suspensions, nasal medical devices and dry powder inhalers using range of technologies. He has held various roles within large Pharmaceutical companies (Pfizer and GSK) and Contract Development Manufacturing Organisations (Patheon – ThermoFisher Scientific and Recipharm). He led formulation, process, analytical development and drug product manufacturing teams ensuring successful clinical manufactures (Phase I to Phase III), technical transfer and scale up for commercial manufacture.

Arul has provided strategic direction for companies in expanding their business offering including control drug development, paediatric drug product development and solubility enhancement.

Arul is passionate about transferring scientific knowledge to the next generation of scientists. As a result, he sits on the advisory board for Greenwich University. He has represented companies as keynote speaker at various conferences and webinars.


Jo Craig

Position: Senior Vice President CMC
Categories: The APS Board

Jo is Senior Vice President CMC (Chemistry Manufacturing & Controls) for NeRRe Therapeutics, a clinical stage biotech company located at the Stevenage Biosciences Catalyst.

Jo is a Pharmacist and has spent her entire career working in the pharmaceutical industry with a focus on pharmaceutical development, product quality and the introduction of new manufacturing technologies. Prior to Jo’s NeRRe Therapeutics role, she held the same role for KaNDy Therapeutics prior to its acquisition by Bayer in 2020.

Previously, Jo spent over 30 years at GlaxoSmithKline where her career spanned many leadership roles in CMC product development, most recently as Vice President of Technology & Strategy, Product Development & Supply. Jo led the technology team at the Medicines Manufacturing Industry Partnership (MMIP) 2017-2018 where she was influential in aligning Pharma and UK Government on future areas for investment as part of the Life Sciences Industrial Strategy. She continues to be involved with medicines manufacturing in the UK contributing to advisory groups. Jo is a Fellow of the Royal Pharmaceutical Society, an Eminent Fellow of the Academy of Pharmaceutical Sciences, UK and has been an Advisor to the APS Board for several years.


Professor Begoña Delgado-Charro

Position: Professor in Biopharmaceutics
Categories: The APS Board

M.B. Delgado Charro is a Professor in biopharmaceutics at the University of Bath.

Begona graduated in Pharmacy, received a PhD in Pharmaceutical Technology, and was a MEC-Fulbright fellow & visiting Assistant Professor at UCSF (1991-1993). She has worked as an academic at the Universities of Santiago de Compostela and Geneva, and since 2004, at the University of Bath where she is currently a Reader. She was a National Expert on Secondment at the European Medicines Agency (10/2015-9/2016) where she worked in business intelligence in drug development and Road-to-Market analysis.

Dr Delgado-Charro research focuses on transdermal and topical drug delivery, the development of optimized methods to treat and prevent nail diseases, non-invasive sampling for drug monitoring and pharmacokinetics, and the assessment of topical bioavailability and bioequivalence. Her work has been funded by several private and public sponsors and her scholastic work (Scopus author ID: 7003434711) includes 105 peer-reviewed scientific articles, 10 book chapters, and several patent applications. Her academic work focuses on the areas of pharmacokinetics and pharmaceutics in the frame of Pharmacy and Pharmacology degrees.


Professor Ryan Donnelly

Position: Chair in Pharmaceutical Technology
Categories: The APS Board

Professor Ryan Donnelly holds the Chair in Pharmaceutical Technology at Queen’s University Belfast and is Director of QUB’s interdisciplinary research programme Materials & Advanced Technologies for Healthcare (MATCH). His personal research is centred on design and physicochemical characterisation of advanced polymeric drug delivery systems for transdermal and intradermal drug delivery, with a strong emphasis on improving patient outcomes. He is currently developing a range of novel microneedle technologies through independent research, but also in collaboration with several major pharma partners.

He has obtained substantial UK Research Council, charity and industrial funding and authored over 300 peer-reviewed publications (H-index = 58), including 6 patent applications, 6 textbooks, 23 book chapters and approximately 250 full papers. He has been an invited speaker at numerous national and international conferences. Professor Donnelly is Europe/Africa Editor of Drug Delivery & Translational Research and the Controlled Release Society’s Communications Chair. He has won the Academy of Pharmaceutical Science’s Innovative Science Award (2020), Evonik’s Resomer Award (2018), the Controlled Release Society’s Young Investigator Award (2016), BBSRC Innovator of the Year and the American Association of Pharmaceutical Scientists Pharmaceutical Research Meritorious Manuscript Award (2013), the GSK Emerging Scientist Award (2012) and the Royal Pharmaceutical Society’s Science Award (2011).


Professor Mohammad Najlah

Position: Professor in pharmaceutics and nanomedicine
Categories: The APS Board

Professor Mohammad Najlah is a Professor in pharmaceutics and nanomedicine at Anglia Ruskin University

He has extensive experience as a teacher, researcher, and manager. Mohammad took a pharmacy degree followed by a postgraduate diploma (Industrial Pharmacy) at Damascus University and obtained his PhD from the University of Manchester. He has an excellent research profile focusing on the development of drug delivery nano-systems for enhanced bioavailability and optimised therapeutic effects. Working within the interface between industry and academia allows Mohammad to assimilate, then transfer knowledge between sectors to valuable effect. His research on developing scaling-up technologies for nanomedicines has attracted several collaborations with industries, which led to several KTP and KEEP+ projects funded by Innovate UK and European Regional Development Fund, respectively. Mohammad is mainly interested in repurposing safe drugs and natural compounds for anticancer therapy. He has published over 80 peer-reviewed publications in the field of pharmaceutical nanotechnology, filed a patent on novel non-toxic anticancer agents and supervised PhD students and post-doc researchers.

At ARU, Mohammad has established and grown the Pharmaceutical Research Group based entirely on externally funded projects and led the establishment of £3.4 million budgeted multifunctional Lab designed to deliver multidisciplinary education and conduct research for transitional science. He served in several managerial roles where he led the establishment of new undergraduate and postgraduate programmes and has gained extensive experience in study management, supporting research activities and identifying the individual support needs of research and ancillary staff.


Dr Bahijja Raimi-Abraham

Position: Lecturer in Pharmaceutics
Categories: The APS Board

Dr Bahijja Raimi-Abraham is a pharmacist, Lecturer in Pharmaceutics at King’s College London and Founder of King’s College London Fight the Fakes and Academic Lead. She leads her research group “The Raimi-Abraham Group”. Her research to date has been in pharmaceutical materials and innovative manufacture. More recently she has focused her research efforts within the therapeutic and drug development aspects of malaria.

Prior to her current position as Lecturer in Pharmaceutics at King’s College London, Dr. Raimi-Abraham held positions at University College London (UCL) as an Engineering and Physical Sciences Research Council (EPSRC) postdoctoral researcher position and at the European Medicines Agency (EMA) as a seconded Quality National Expert.

Dr. Raimi-Abraham is the first graduate of the University of East Anglia School of Pharmacy to be awarded a Ph.D. and more recently won the Outstanding Woman in STEM Precious Award.

Dr Raimi-Abraham has an extensive and original public engagement portfolio which includes uniquely exploring the use of street art to engage public with Science, Technology, Engineering and Mathematics (STEM) research through her social enterprise STEAM:ED Collective, a TEDx talk (TEDx Talk title “Elements of Change: Becoming an Independent Researcher) and a “Go and No-go pills” Somerset House 24/7 exhibition, visited by ~35,000 people (Oct. 2019 – Feb. 2020)). More recently hosting a weekly podcast, Monday Science which discusses the latest in Science, Health and Technology. Dr Raimi-Abraham’s work in research informed teaching has also been recognised by the Nuffield Foundation.


Dr Philipp Seib

Position: Registered pharmacist and a Reader
Categories: The APS Board

Philipp is a registered pharmacist and a Reader in Pharmaceutical Materials at the Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow

He obtained his BPharm and MSc from King’s College London and his PhD (2005) in drug delivery from Cardiff University. He conducted postdoctoral research at the Technical University Dresden (Germany) and Tufts University (Boston, USA). He is a Fellow of the Academy of Pharmaceutical Sciences and a Fellow of the Higher Education Academy. His research interest lies at the interface of cell biology, drug delivery and material science. His research mission involves top-down, challenge-based activities centred on developing pharmaceutical materials for healthcare technologies, with the ultimate goal of improving patient outcomes.